1 hr ago | AmericanBankingNews.com
's stock had its "buy" rating restated by equities researchers at Societe Generale in a report issued on Thursday, Stock Ratings Network.com reports.
5 hrs ago | The Standard
Finnish researchers unveiled new data to link the Pandemrix flu vaccine made by British drug company GlaxoSmithKline to a higher risk of the sleeping disorder narcolepsy in adults.
7 hrs ago | Pharmaceutical Technology
GlaxoSmithKline and the Biomedical Advanced Research and Development Authority , part of the United States Department of Health and Human Services , have agreed to a collaboration that will support the development of several antibiotics to fight antibiotic resistance and bioterrorism, GSK announced in a press release .
11 hrs ago | Forbes.com
This post was written by Steven E. Nissen MD, the Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic.
15 hrs ago | BioSpace
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! GlaxoSmithKline Plc's H1N1 pandemic flu shot may put adults at higher risk of developing narcolepsy, not only children as previous studies found, Finland's National Institute for Health and Welfare said on Thursday.
18 hrs ago | The New Zealand Herald
New Zealand is running low on chickenpox vaccines as more parents seek to have their children immunised and as winter approaches.
's stock had its "underperform" rating restated by analysts at BNP Paribas in a research report issued to clients and investors on Wednesday, ARN reports.
GlaxoSmithKline says some manufacturing from the shuttering of an Australian packaging site will be picked up by Aspen and local third-party contractors.
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! by Richard Daverman, PhD May 21, 2013 -- Want to increase revenues in China? You might try lowering prices.
Olivia Walker and Rod Ashton working on the Ventolin production line at GlaxoSmithKline pharmaceutical plant at Boronia.
Ever since GSK in December 2006 broke a then industry record by licensing a drug for leukaemia from Genmab for 1.6bn, taking a 10 per cent stake in the process, the pharmaceutical world has expected GSK to one day launch a full-scale cash offer.
Theravance and Elan announced in a press release that Elan will purchase a participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline : RELVAR ELLIPTA/BREO ELLIPTA , ANORO ELLIPTA , MABA monotherapy , and vilanterol monotherapy.
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today announced clinical progress with its Anti-Notch2/3 product candidate, which will trigger an $8 million milestone payment from the company's strategic collaborator GlaxoSmithKline .